Patient number
|
Sex
|
Age at diagnosis, years
|
Translocation type
|
TNM at diagnosis
|
FISH analysis
|
Karnofsky score
|
Heng score (IDMC criteria)
|
First treatment line
|
Response to 1st line
|
PFS (mo)
|
Immunotherapy treatment
|
ICI line
|
Response to ICI
|
Duration of response (mo)
|
Deseased
|
Survival (mo)
|
---|
1
|
F
|
25
|
TFE B
|
T3N2M1
|
available
|
100
|
2
|
Sunitinib
|
PD
|
2
|
Ipilimumab
|
4
|
PR
|
9.0
|
no
|
40
|
2
|
F
|
3
|
TFE 3+
|
TxN0M0
|
available
|
100
|
1
|
Sunitinib
|
PD
|
1
|
Ipilimumab
|
5
|
PD
|
2.5
|
yes
|
23.5
|
3
|
F
|
13.7
|
TFE 3+
|
T2N + M+
|
available
|
60
|
3
|
Pazopanib
|
PR
|
4
|
Ipilimumab
|
3
|
PD
|
2,0
|
yes
|
20.7
|
4
|
F
|
10
|
TFE 3+
|
TxNxM0
|
available
|
< 80
|
1
|
Everolimus
|
PD
|
4.4
|
Atezolizumab
|
2
|
PD
|
0.8
|
no
|
19
|
5
|
F
|
35.5
|
TFE 3+
|
T2bN1Mx
|
available
|
100
|
4
|
Sunitinib
|
PD
|
4.4
|
Nivolumab
|
5
|
PD
|
1.0
|
yes
|
24.5
|
6
|
M
|
22
|
TFE 3+
|
pT1bNxM0
|
available
|
100
|
1
|
Sunitinib
|
PD
|
1
|
Nivolumab
|
2
|
PR
|
8.3
|
no
|
17
|
7
|
F
|
26.7
|
TFE 3+
|
pT1bNxMxR1
|
available
|
100
|
0
|
Sunitinib
|
PD
|
4
|
Nivolumab
|
3
|
PD
|
2.4
|
no
|
25
|
8
|
M
|
60.7
|
TFE B
|
pT3cN0M1R1
|
available
|
100
|
1
|
Sunitinib
|
PD
|
3.1
|
Nivolumab
|
3
|
PD
|
2.5
|
yes
|
19.5
|
9
|
F
|
35
|
TFE 3+
|
pT3aN1Mx
|
available
|
100
|
1
|
Sunitinib
|
PD
|
2.7
|
Nivolumab
|
2
|
PD
|
1.0
|
yes
|
9.6
|
10
|
M
|
41.9
|
TFE 3+
|
pT3bN1Mx
|
no
|
90
|
1
|
Pazopanib
|
PD
|
1.2
|
Nivolumab
|
2
|
PD
|
1.4
|
yes
|
8.5
|
11
|
F
|
35.1
|
TFE 3+
|
T3cN0M0
|
available
|
90
|
1
|
High dose IL-2
|
PD
|
0.1
|
MEDI4736 + Tremelimumab
|
4
|
PD
|
2.4
|
yes
|
16.9
|
12
|
F
|
16.1
|
TFE 3+
|
T1aN1M1
|
available
|
70
|
2
|
Sunitinib +nivolumab
|
SD
|
3.2
|
Sunitinib +nivolumab
|
1
|
PR
|
3.2
|
yes
|
7.6
|
13
|
F
|
79.5
|
TFE 3+
|
T3aN0M0
|
available
|
60
|
1
|
Temsirolimus
|
SD
|
1.2
|
Nivolumab
|
5
|
PD
|
1.0
|
yes
|
17.3
|
14
|
F
|
54
|
TFE 3+
|
T2aN0M1
|
available
|
80
|
2
|
Pazopanib
|
PR
|
17.2
|
Nivolumab
|
2
|
SD
|
15.4
|
no
|
84.6
|
15
|
F
|
42.8
|
TFE 3+
|
T3N + M+
|
available
|
100
|
1
|
Sunitinib
|
SD
|
22
|
Nivolumab
|
4
|
PD
|
9.0
|
no
|
59
|
16
|
M
|
32
|
TFE B
|
T3bN0M1
|
available
|
80
|
0
|
Sunitinib
|
PD
|
1
|
Nivolumab
|
2
|
SD
|
14
|
no
|
25
|
17
|
F
|
29.4
|
TFE 3+
|
T4N1M1
|
available
|
80
|
5
|
Pazopanib
|
SD
|
3
|
Nivolumab
|
2
|
PD
|
3
|
no
|
4
|
18
|
F
|
26.7
|
TFE 3+
|
NA
|
no
|
90
|
2
|
Sunitinib
|
SD
|
15
|
pembro +41BB agonist
|
3
|
PR
|
30
|
yes
|
60
|
19
|
F
|
49
|
TFE 3+
|
pT4pN1pM1
|
no
|
NA
|
1
|
Sunitinib
|
PD
|
3
|
Nivolumab
|
2
|
SD
|
8.5
|
yes
|
19
|
20
|
F
|
43
|
TFE 3+
|
T3bN0M0
|
available
|
90
|
1
|
Sunitinib
|
PD
|
1.5
|
Nivolumab
|
3
|
PD
|
1
|
yes
|
8
|
21
|
F
|
63
|
TFE 3+
|
pT3aNxMx
|
available
|
90
|
1
|
Sunitinib
|
PD
|
6
|
Nivolumab
|
5
|
PD
|
2
|
yes
|
24
|
22
|
F
|
48.2
|
TFE 3+
|
T3NxM1
|
available
|
70
|
3
|
Sunitinib
|
PD
|
3
|
Nivolumab
|
2
|
PD
|
2
|
no
|
5
|
23
|
F
|
45
|
TFE 3+
|
pT3aNxM1R1
|
available
|
80
|
1
|
Sunitinib
|
PD
|
2
|
Nivolumab
|
2
|
PD
|
3
|
yes
|
9
|
24
|
F
|
24
|
TFE 3+
|
pT2bN1
|
available
|
NA
|
1
|
Sorafenib
|
SD
|
12
|
Nivolumab
|
3
|
PD
|
4
|
no
|
70
|
- PR: partial response; SD: stable disease; PD: progressive disease